Ningetinib not checked

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
2 in total
Targets
—
None known yet

What this is

How it works
Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
Tested for
Stage IV Non-small Cell Lung Cancer, Advanced HCC
Main trialPhase 2
“This is a phase II, open label, multicenter study in subjects with advanced non-small cell lung cancer.”In the company’s words, NCT03838848 on ClinicalTrials.gov

Other drugs for Stage IV Non-small Cell Lung Cancer

All 560 drugs for Stage IV Non-small Cell Lung Cancer

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Terminated 30 Jul 2022 KN046 in Patients With Advanced Non-small Cell Lung Cancer
Phase 1/2Terminated 30 May 2022 KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Ningetinib

Following is part of Solo: you see every change to Ningetinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in